New faculty join CCR each year to contribute to our work of making breakthrough scientific discoveries to find cures and treatments for cancer.
Grégoire Altan-Bonnet, Ph.D.
Grégoire Altan-Bonnet, Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Laboratory of Integrative Cancer Immunology. Dr. Altan-Bonnet and his team develop actionable models of the immune system and its response to cancer, with the goal of designing and optimizing new immunotherapies.
Christina M. Annunziata, M.D., Ph.D.
Christina M. Annunziata, M.D., Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Women’s Malignancies Branch. Dr. Annunziata translates bench research to clinical trials focusing on mechanisms underlying NF-kappaB molecular signal transduction in ovarian cancer.
Erin L. Davies, Ph.D.
Erin L. Davies, Ph.D., has joined the Cancer and Developmental Biology Laboratory as a Stadtman Tenure-Track Investigator. She is investigating the embryonic origin and regulation of adult pluripotent stem cells required for tissue maintenance, whole-body regeneration and reproduction in planarian flatworms.
Thomas Gonatopoulos-Pournatzis, Ph.D.
Thomas Gonatopoulos-Pournatzis, Ph.D., has joined the RNA Biology Laboratory as a Stadtman Tenure-Track Investigator and is a member of the NIH Distinguished Scholars Program. His lab utilizes functional genomics to uncover RNA regulatory mechanisms that underlie cell fate decisions and how disruption of these processes contribute to disease states.
Christian S. Hinrichs, M.D.
Christian S. Hinrichs, M.D., was awarded tenure at NIH and appointed to Senior Investigator in the Genitourinary Malignancies Branch. Dr. Hinrichs discovered personalized cellular and gene therapies for HPV+ cancers and researched immunotherapy for HPV+ cancers including cervical, oropharyngeal, anal, vulvar, vaginal and penile malignancies.
Kazusa Ishii, M.D., M.P.H.
Kazusa Ishii, M.D., M.P.H., has joined the Genitourinary Malignancies Branch as part of CCR’s Physician-Scientist Early Investigator Program. Dr. Ishii researches cell therapy for various hematologic malignancies and non-malignant diseases.
James N. Kochenderfer, M.D.
James N. Kochenderfer, M.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Surgery Branch. Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia and multiple myeloma.
Jadranka Lončarek, Ph.D.
Jadranka Lončarek, Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Laboratory of Protein Dynamics and Signaling. Dr. Lončarek studies the fundamentals of centrosome biology: their biogenesis, architecture and cellular processes associated with their activity.
Christian T. Mayer, Ph.D.
Christian T. Mayer, Ph.D., has joined the Experimental Immunology Branch as a Stadtman Tenure-Track Investigator. His research explores immunoregulatory networks, particularly those involving cell death, in health and disease.
Jordan L. Meier, Ph.D.
Jordan L. Meier, Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Chemical Biology Laboratory. Dr. Meier’s work focuses on the development of chemical approaches to study epigenetic signaling and its relationship to cellular metabolism.
Barry R. O’Keefe, Ph.D.
Barry R. O’Keefe, Ph.D., has been appointed Director of and Senior Scientist in the Molecular Targets Program. Dr. O’Keefe pioneered the discovery of biotherapeutics from natural products. He also specializes in the analysis and exploitation of protein-ligand interactions for both high-throughput screening and compound characterization.
Udo Rudloff, M.D., Ph.D.
Udo Rudloff, M.D., Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Pediatric Oncology Branch. Dr. Rudloff’s work is focused on the discovery, translation and early phase clinical testing of novel therapies for patients with pancreatic and other solid organ cancers.
Christina I. Schroeder, Ph.D.
Christina I. Schroeder, Ph.D., has joined the Chemical Biology Laboratory as a Stadtman Tenure-Track Investigator. Her research uses bioactive peptide engineering of complex venom-derived peptides in order to investigate the therapeutic potential of ion channels upregulated in cancer.
Brad St. Croix, Ph.D.
Brad St. Croix, Ph.D., has been appointed as a Senior Scientist in the Mouse Cancer Genetics Program. His research focuses on the molecules involved in human tumor angiogenesis and utilizes mouse models to translate new molecular information on angiogenesis into the development of novel diagnostics and cancer therapeutics.
Travis H. Stracker, Ph.D.
Travis H. Stracker, Ph.D., has been appointed as a Tenure-Track Investigator in the Radiation Oncology Branch. Dr. Stracker’s research focuses on understanding how cells respond to DNA damage and maintain genomic stability.
Kandice Tanner, Ph.D.
Kandice Tanner, Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Laboratory of Cell Biology. Dr. Tanner’s research focuses on understanding the metastatic traits that allow tumor cells to colonize secondary organs.
Christopher J. Westlake, Ph.D.
Christopher J. Westlake, Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Laboratory of Cell and Developmental Signaling. Dr. Westlake studies membrane trafficking pathways important in ciliopathy, which are diseases linked to primary cilia dysfunction and cancer.
Matthew T. Wolf, Ph.D.
Matthew T. Wolf, Ph.D., has joined the Laboratory of Cancer Immunometabolism as a Stadtman Tenure-Track Investigator. He studies immunomodulatory biomaterials to augment cancer immunotherapy.
Colin C.C. Wu, Ph.D.
Colin C.C. Wu, Ph.D., has joined the RNA Biology Laboratory as a Stadtman Tenure-Track Investigator. His research explores the role of the ribosome in stress response signaling pathways and translational regulation to collect insights that can be used to guide the prevention and treatment of human diseases.
Ryan Young, Ph.D.
Ryan Young, Ph.D., has joined the Lymphoid Malignancies Branch as a Stadtman Tenure-Track Investigator. He uses proteogenomic technologies to elucidate novel modes of pathogenic signaling in multiple myeloma and lymphoma.